missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Novus Biologicals™ Complement C3 Antibody (NGM621) - Humanized, Novus Biologicals™
Human Monoclonal Antibody
Brand: Novus Biologicals™ NBP3-28216-50ug
This item is not returnable.
View return policy
Description
Complement C3 Monoclonal antibody specifically detects Complement C3 in Human samples. It is validated for Flow Cytometry,ELISA,Functional Assay
Specifications
| Complement C3 | |
| Monoclonal | |
| Unconjugated | |
| P01024 | |
| Human | |
| Protein A purified | |
| RUO | |
| Primary | |
| Reconstitute with sterile, distilled water to a final concentration of 1 mg/mL. Gently shake to solubilize completely. Do not vortex. | |
| Store at -20°C in powder form. Store at -80°C once reconstituted. | |
| IgG1 |
| Flow Cytometry, ELISA, Functional Assay | |
| NGM621 | |
| Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2) | |
| Acylation Stimulating Protein, acylation-stimulating protein cleavage product, AHUS5, ARMD9, ASP, C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, C3a, C3a anaphylatoxin, C3adesArg, C3b, C3bc, C3-beta-c, complement C3, Complement C3 alpha chain, Complement C3 beta chain, Complement C3b alpha' chain, Complement C3c alpha' chain fragment 1, Complement C3c alpha' chain fragment 2, Complement C3d fragment, Complement C3dg fragment, Complement C3f fragment, Complement C3g fragment, complement component 3, complement component C3, complement component C3a, complement component C3b, CPAMD1, EC 3.4.21.43, epididymis secretory sperm binding protein Li 62p, HEL-S-62p, prepro-C3 | |
| Complement C3 | |
| 50 μg | |
| Angiogenesis, Apoptosis, Autoimmune Diseases, Immunology, Inflammation, Innate Immunity, Mesenchymal Stem Cell Markers, Neurodegeneration, Neuroscience, Signal Transduction | |
| 718 | |
| Human | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction